Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST<sub>2</sub> in Mediating Ligand Effects

Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST<sub>2</sub> in Mediating Ligand Effects

First-generation somatostatin receptor ligands (fg-SRLs), such as octreotide (OCT), represent the first-line medical therapy in acromegaly. Fg-SRLs show a preferential binding affinity for somatostatin receptor subtype-2 (SST<sub>2</sub>), while the second-generation ligand, pasireotide...

Full description

Bibliographic Details
Main Authors: Jessica Amarù, Federica Barbieri, Marica Arvigo, Agnese Solari, Adriana Bajetto, Federica Nista, Claudia Campana, Gabriele Gaggero, Alessandro Prior, Diego Criminelli Rossi, Gianluigi Zona, Diego Ferone, Tullio Florio, Federico Gatto
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
GH-secreting pituitary tumors
somatostatin receptor ligands
octreotide
pasireotide
GH4C1 cell line
acromegaly
Online Access:https://www.mdpi.com/2072-6694/13/8/1816

Internet

https://www.mdpi.com/2072-6694/13/8/1816

Similar Items